BioDelivery Sciences International (BDSI) Earning Somewhat Favorable Media Coverage, Accern Reports

News articles about BioDelivery Sciences International (NASDAQ:BDSI) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioDelivery Sciences International earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 46.8626687696818 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:

Shares of BioDelivery Sciences International (NASDAQ:BDSI) opened at $2.80 on Friday. BioDelivery Sciences International has a 1 year low of $1.55 and a 1 year high of $3.60. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.07 and a current ratio of 1.28.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The company had revenue of $11.25 million during the quarter, compared to the consensus estimate of $9.40 million. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The company’s revenue was up 215.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.30) EPS. research analysts expect that BioDelivery Sciences International will post 0.16 EPS for the current fiscal year.

Several research firms recently issued reports on BDSI. ValuEngine downgraded shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Roth Capital set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, October 12th. HC Wainwright set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Friday, October 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.50 price target on shares of BioDelivery Sciences International in a research note on Monday, August 14th. Finally, Piper Jaffray Companies set a $4.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $4.29.

In other news, CEO Mark A. Sirgo sold 50,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $2.95, for a total value of $147,500.00. Following the completion of the sale, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at approximately $4,452,322.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mark A. Sirgo sold 24,516 shares of the business’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $2.75, for a total transaction of $67,419.00. Following the completion of the sale, the chief executive officer now directly owns 1,509,262 shares of the company’s stock, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. Insiders sold a total of 402,127 shares of company stock valued at $1,142,798 in the last three months. Insiders own 9.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “BioDelivery Sciences International (BDSI) Earning Somewhat Favorable Media Coverage, Accern Reports” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://transcriptdaily.com/2017/12/10/biodelivery-sciences-international-bdsi-earning-somewhat-favorable-media-coverage-accern-reports.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply